

Supplementary Table 2. Common therapies for platinum-sensitive epithelial ovarian cancer

Traditional Chemotherapy

- A. Paclitaxel/carboplatin every three weeks for 6-8 cycles¹²
- B. Gemcitabine/carboplatin every three weeks for 6 cycles¹³
- C. Liposomal doxorubicin/carboplatin every four weeks for 6 cycles¹⁴

**Tradition Chemotherapy +
Bevacizumab**

- A. Gemcitabine/carboplatin/bevacizumab every three weeks for 6 cycles^{a 15}
- B. Paclitaxel/Carboplatin/Bevacizumab every three weeks for 6 cycles^{a 16}

PARPi treatment

- A. Rucaparib^{b,c 17}

Maintenance PARPi following response to platinum therapy

- A. Olaparib^{b, d 18}
- B. Niraparib^{b 19}
- C. Rucaparib^{b 16}

^aBevacizumab continued until disease progression or unacceptable toxicity

^bPARPi continued until disease progression or unacceptable toxicity

^cgermline BRCA1 or BRCA2 mutations patients or somatic loss of heterozygosity (high)

^dgermline BRCA1 or BRCA2 deficient patients only